Theranostics 2021; 11(20):9805-9820. doi:10.7150/thno.65203 This issue

Research Paper

Interleukin-4 and interleukin-13 induce different metabolic profiles in microglia and macrophages that relate with divergent outcomes after spinal cord injury

Jesus Amo-Aparicio1, Joana Garcia-Garcia1, Isaac Francos-Quijorna2, Andrea Urpi1, Anna Esteve-Codina3,4, Marta Gut3,4, Albert Quintana1, Ruben Lopez-Vales1,5✉

1. Departament de Biologia Cellular, Fisiologia i Immunologia, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, 08193, Catalonia, Spain.
2. Regeneration Group, Wolfson Centre for Age-Related Diseases, IoPPN, King's College London, London, SE11YR, UK.
3. CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Baldiri i Reixac 4, Barcelona, 08028, Catalonia, Spain.
4. Universitat Pompeu Fabra (UPF), Barcelona, 08020, Catalonia, Spain.
5. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED).

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Amo-Aparicio J, Garcia-Garcia J, Francos-Quijorna I, Urpi A, Esteve-Codina A, Gut M, Quintana A, Lopez-Vales R. Interleukin-4 and interleukin-13 induce different metabolic profiles in microglia and macrophages that relate with divergent outcomes after spinal cord injury. Theranostics 2021; 11(20):9805-9820. doi:10.7150/thno.65203. Available from https://www.thno.org/v11p9805.htm

File import instruction

Abstract

Graphic abstract

Background: Microglia and macrophages adopt a pro-inflammatory phenotype after spinal cord injury (SCI), what is thought to contribute to secondary tissue degeneration. We previously reported that this is due, in part, to the low levels of anti-inflammatory cytokines, such as IL-4. Since IL-13 and IL-4 share receptors and both cytokines drive microglia and macrophages towards an anti-inflammatory phenotype in vitro, here we studied whether administration of IL-13 and IL-4 after SCI leads to beneficial effects.

Methods: We injected mice with recombinant IL-13 or IL-4 at 48 h after SCI and assessed their effects on microglia and macrophage phenotype and functional outcomes. We also performed RNA sequencing analysis of macrophages and microglia sorted from the injured spinal cords of mice treated with IL-13 or IL-4 and evaluated the metabolic state of these cells by using Seahorse technology.

Results: We observed that IL-13 induced the expression of anti-inflammatory markers in microglia and macrophages after SCI but, in contrast to IL-4, it failed to mediate functional recovery. We found that these two cytokines induced different gene signatures in microglia and macrophages after SCI and that IL-4, in contrast to IL-13, shifted microglia and macrophage metabolism from glycolytic to oxidative phosphorylation. These findings were further confirmed by measuring the metabolic profile of these cells. Importantly, we also revealed that macrophages stimulated with IL-4 or IL-13 are not deleterious to neurons, but they become cytotoxic when oxidative metabolism is blocked. This suggests that the metabolic shift, from glycolysis to oxidative phosphorylation, is required to minimize the cytotoxic responses of microglia and macrophages.

Conclusions: These results reveal that the metabolic fitness of microglia and macrophages after SCI contributes to secondary damage and that strategies aimed at boosting oxidative phosphorylation might be a novel approach to minimize the deleterious actions of microglia and macrophages in neurotrauma.

Keywords: interleukin 4, interleukin 13, immune metabolism, polarization, spinal cord injury